7 Results for "

PKA-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "PKA-IN-2" in MCE Product Catalog:

27
27 Cited Publications
Cat. No.: HY-N6732
CAS No.: 99533-80-9
Synonyms: SF2370; Antibiotic K 252a; Antibiotic SF 2370
K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca 2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively [2]. K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-15424
CAS No.: 24386-93-4
Purity:  99.64%
Synonyms: NSC 113939; 5-ITu
Target:  

Adenosine Kinase

Research Areas:  

Cancer

5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin [2] .
loading...
    loading...
Cat. No.: HY-176532
Target:  

PKA

Research Areas:  

Cancer

PKA-IN-2 (Compound j1) is a serine/threonine kinase J-PKAcα-targeting inhibitor with an IC50 of 6.3 nM. PKA-IN-2 can be used for liver cancer like fibrolamellar hepatocellular carcinoma research .
loading...
    loading...
Cat. No.: HY-148868A
CAS No.: 1334108-00-7
Target:  

Akt CDK

Research Areas:  

Cancer

Akt1&PKA-IN-2 (Compound R-29) is a AKT1 and PKA inhibitor with selectivity for CDK2, with IC50 values of 0.007 and 0.01 μM, respectively. Akt1&PKA-IN-2 is applicable for cancer research .
loading...
    loading...
Cat. No.: HY-15424R
CAS No.: 24386-93-4
Synonyms: NSC 113939 (Standard); 5-ITu (Standard)
Research Areas:  

Cancer

5-Iodotubercidin (Standard) is the analytical standard of 5-Iodotubercidin. This product is intended for research and analytical applications. 5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin [2] .
loading...
    loading...
Cat. No.: HY-P10319
Target:  

PKA

Research Areas:  

Cardiovascular Disease Cancer

RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
loading...
    loading...
Cat. No.: HY-184145
Research Areas:  

Cancer

AKT1-IN-13 is an orally active AKT1 inhibitor with an IC50 of 5.17 μM. AKT1-IN-13 also exhibits high inhibitory activity against PAK1, PKA, MAP2K1 (MEK1 / MAPKK1) and MAPK1 (ERK2). AKT1-IN-13 induces cell apoptosis, activates the pro-apoptotic protein BAX, inhibits the anti-apoptotic protein Bcl-2, and activates caspase 3 simultaneously. As a cytotoxic agent, AKT1-IN-13 exerts a killing effect on orthotopically transplanted liver cancer in an AKT1-dependent manner. AKT1-IN-13 can be used in studies related to hepatocellular carcinoma .
loading...
    loading...